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Abstract
In the classical human leukocyte antigen (HLA) class I antigen processing and presentation pathway, the antigenic
peptides are generated from viral proteins by multiple proteolytic cleavages of the proteasome (and in some cases
other cytosolic proteases) and transported to the endoplasmic reticulum (ER) lumen where they are exposed to
aminopeptidase activity. In human cells, two different ER-resident enzymes, ERAP1 and ERAP2, can trim the N-
terminally extended residues of peptide precursors. In this study, the possible cooperative effect of generating five
naturally processed HLA-B27 ligands by both proteases was analyzed. We identified differences in the products
obtained with increased detection of natural HLA-B27 ligands by comparing double versus single enzyme digestions
by mass spectrometry analysis. These in vitro data suggest that each enzyme can use the degradation products of
the other as a substrate for new N-terminal trimming, indicating concerted aminoproteolytic activity of ERAP 1 and
ERAP2.
Citation: Lorente E, Barriga A, Johnstone C, Mir C, Jiménez M, et al. (2013) Concerted In Vitro Trimming of Viral HLA-B27-Restricted Ligands by Human
ERAP1 and ERAP2 Aminopeptidases. PLoS ONE 8(11): e79596. doi:10.1371/journal.pone.0079596
Editor: Sylvie  Le Gall, Massachusetts General Hospital, United States of America
Received April 11, 2013; Accepted September 24, 2013; Published November 1, 2013
Copyright: © 2013 Lorente et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants to D. L. from the Ministerio de Ciencia e Innovación. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: dlopez@isciii.es
Introduction
Newly synthesized viral proteins are proteolytically
processed, mainly by the action of proteasomes [1] and in
some cases of other cytosolic proteases [2]. This protein
degradation generates an extremely diverse pool of substrates,
both in sequence and length, that are translocated to the lumen
of the endoplasmic reticulum (ER) by transporters associated
with antigen processing. Among them, only a small fraction
with a correct epitope or NH2-terminally-extended precursors
can be used for antigen presentation by direct epitope binding
to HLA class I molecules or by precursor editing and
customization, respectively, to yield the final viral epitope by
ER-resident aminopeptidase activity. Later, binding of a viral
peptide to HLA class I molecules in the ER stabilizes the
nascent antigenic complexes and allows for their subsequent
transport to the cell membrane, where they are exposed to
antiviral CD8+ cytotoxic T lymphocyte (CTL) activity that
recognizes and kills virus-infected cells [3].
The ER-resident enzymatic activity that trims N-terminally
extended residues of peptide precursors to their final length
has been identified as the ER aminopeptidase associated with
antigen processing (ERAAP) in mice [4] and ER
aminopeptidase 1 (ERAP1) in humans [5,6]. Additionally, a
second ER aminopeptidase, ERAP2, also trims certain
precursors to HLA class I-presented antigenic peptides in
humans but not in mice [7,8]. The homology between the two
human enzymes is less (approximately 50% identity) compared
to the human ERAP1 and mouse ERAAP homologs, according
to their non-redundant trimming activities. ERAP1 and ERAP2
form complexes in low amounts [9], and a complementary and
concerted function of these human trimming aminopeptidases
in HLA class I peptide presentation with a single substrate has
been previously described using a 15-mer peptide, derived
from the HIV IIIB envelope protein. Six N-terminal extended
residues regarding the shortest natural 9-mer epitope
presented by the H-2Ld-restricted CTL response in BALB/C
mice [10], were cooperatively trimmed in vitro to generate the
9-mer epitope by concerted activity of these two
aminopeptidases [9]. Therefore, is this case of a rare N-
terminal cooperative trimming xenogeneic event? Or,
conversely, do ERAP1 and ERAP2 show a broad capacity to
cooperatively generate multiple HLA class I viral epitopes? To
answer these questions, the possible cooperative effect of both
of these metallopeptidases was analyzed using N-terminal
extended precursors of five naturally processed HLA-B27
ligands, 9, 10, and 11 amino acids in length, derived from
human respiratory syncytial virus (HRSV) [11]. This in vitro
study demonstrates differences in the products obtained from
single digestions when compared with the mixture of both
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Peptides were synthesized in a peptide synthesizer (model
433A; Applied Biosystems, Foster City, CA) and purified by
RP-HPLC (purity > 99%, for an example see Figure 1A).
Identities were confirmed by matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF) mass spectrometry.
Digestion with recombinant ERAP enzymes
Recombinant purified human ERAP1181Q528R and ERAP2392K
enzymes (R&D Systems, Minneapolis, MN, USA) were
incubated for the indicated periods at 37°C with purified
synthetic peptides at the indicated molar enzyme/substrate
ratios in 25 mM Tris and pH 8. The addition of trifluoroacetic
acid to a final concentration of 0.2% stopped the digestions and
denatured the proteins. In the experiments, different E/S ratios
(1:400, 1:800, and 1:2,000) were used with similar results, thus
the 1:800 E/S ratio was selected for graphic purposes.
MALDI-TOF mass spectrometry
MALDI-TOF mass spectrometry was performed using a
Reflex IV instrument (Brucker-Franzen Analytik, Bremen,
Germany) operating in the positive ion reflection mode. One μl
of sample was mixed with 0,8 μl of saturated α-
cyanohydroxycinnamic acid matrix in the same solution. One
microliter of the mixture was dried and subjected to analysis as
previously described [12].
The intensity peaks obtained at each time point for all
peptides were added and taken as 100% for each time point
and depicted as stacked area charts. Data shown are
representative of 2-4 different experiments. To show both
sensitivity and specificity of mass spectrometry analysis, a
calibration curve of three nested set synthetic peptides is
depicted in Figure S1.
Results
Two natural HRSV 9-mer ligands are efficiently
generated by concerted ERAP1 and ERAP2
aminopeptidase activity
To study susceptibility to aminopeptidase activity,
recombinant ERAP1 was incubated with several 15-mer
synthetic peptide precursors of naturally processed viral HLA-
B27 ligands from HRSV-infected cells described previously
[11]. Cleavage products generated at different enzymatic
digestion times were subsequently analyzed by mass
spectrometry. At time 0 or in the absence of enzyme, this
system allowed the detection of molecular species with the
same monoisotopic m/z as the 15-mer substrate (an example
with the M163-177 synthetic peptide is shown in Figure 1A).
Additionally, minority peaks with a 15-mer m/z less than 16 or
36 Daltons were frequently found (Figure 1A, asterisk),
probably due to the previously reported neutral loss in the
Figure 1.  MALDI-MS analysis of the M163-177 synthetic
peptide digested with purified ERAPs.  M163-177 substrate
(Panel A) was digested overnight with ERAP as follow: ERAP1
at an E/S ratio of 1:800 (panel B), ERAP2 at an E/S ratio of
1:800 (panel C), both ERAP1 and 2 at an E/S ratio of 1:800 for
each enzyme (panel D), and both ERAP1 and 2 at an E/S ratio
of 1:1600 for each enzyme (panel E). MALDI-TOF analysis of
digestions detected M163-177 substrate and N-trimmed peptides,
as well as several adducts and neutral loss of peptides
(marked by an arrow or asterisk, respectively). The m/z range
represented in the x-axis is 1000-1850. The m/z position and
length of each possible N-trimmed peptide is indicated with an
arrow at the base of the figure.
doi: 10.1371/journal.pone.0079596.g001
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peptides under desorption/ionization conditions [12]. After
overnight incubation in the presence of the enzyme, total
cleavage of the M163-177 substrate was observed via detection of
trimmed 12-mer and 13-mer products (Figure 1B). Additionally,
trimmed peptide adducts were found in some experiments
(Figure 1, arrows), as previously reported in similar desorption/
ionization conditions [12].
The results shown in Figure 1 and other intermediate points
are summarized and depicted in Figure 2A for further
clarification. After only 5 minutes in the presence of the
enzyme, major substrate cleavage was observed and trimmed
14-mer, 13-mer, and 11-mer products with a predominant 12-
mer signal were detected (Figure 2A). After 15 minutes, traces
of the 10-mer peptide were also found. After 45 minutes, the
signal of the 9-mer, which is the natural ligand identified in
HRSV-infected cells, was detected. Peptides shorter than the
9-mer were not detected in the experiments.
Next, similar experiments with this 15-mer synthetic peptide
precursor and ERAP2 enzyme were carried out in parallel.
Predominantly untrimmed peptides, following an overnight
incubation, were detected with M163-177 substrate (Figure 2B).
Low levels of several products, including both 9-mers, were
detected in this experiment (Figure 2B).
To test the complementary trimming function of both
aminopeptidases, similar experiments with five 15-mer
synthetic peptide precursors and a mix of both enzymes were
carried out in parallel to individual digestions. Figure 2C shows
the stacked area charts of M163-177 synthetic peptide digested
with the mix of both aminoproteases. The 15-mer M163-177
peptide was more efficiently trimmed to both the short 11-mer
product and especially the natural 9-mer ligand (Table 1) in the
presence of both enzymes (Figure 1D and stacked area charts
2C) than in individual digestions (Figures 1B and 2C, 2A and
2B). Additionally, when the E/S ratio decreased by half, the 11-
mer product was generated more in the enzyme mix than in
individual digestions (Figure 2D versus Figure 2A and 2B),
similar to the production of the natural 9-mer ligand (6% of total
with the mix versus 7% with the sum of individual digestions),
as shown in Table 1.
Similar experiments were performed with the 15-mer NS231-45
synthetic peptide. This substrate was relatively resistant to
ERAP1 activity because low amounts of several N-trimmed
products were detected, even after long enzymatic reaction
times (Figure 2E); however, amounts of 9-mer natural ligand
were detected (Table 1). Also, ERAP2 was incapable of
trimming the NS231-45 synthetic peptide, as only low amounts of
the 14-mer and 12-mer products were detected at all analyzed
times (Figure 2F).
Similarly to M163-177 peptide, the NS231-45 peptide experiments
with a mix of both ERAP enzymes demonstrated increased
NS231-45 precursor destruction and trimming rates to shorter
peptides (Figure 2G versus Figure 2E and 2F and Table 1).
This observation held true even when the E/S ratio was
decreased by half: 11% of the 9-mer natural ligand was
produced in the enzyme mix condition versus 7% with ERAP1
(Table 1). These data show that the combined activity of both
enzymes improves the in vitro generation efficiency of both
natural HLA-B27 ligands.
Differential role of combined ERAP1 and ERAP2
activity in the natural HRSV 11-mer ligand generation
Similar to the M163-177 synthetic peptide, the incubation of 15-
mer N191-205 precursor with ERAP1 predominantly cleaved the
substrate and different N-trimmed products were detected,
although without a major product (Figure 3A), and low levels of
several products, including both 9-mers, were detected in the
experiment with ERAP2 (Figure 3B). The activity of ERAP1
(Figure 3A) but not ERAP2 (Figure 3B) over N191-205 synthetic
precursor efficiently generated the previously identified by
mass spectrometry analysis natural 11mer ligand in addition to
other trimmed products (Table 1).
Furthermore, the comparison between single versus double
enzymatic source trimming of this N191-205 synthetic peptide
revealed a strong reduction in the amounts of both the natural
11-mer ligand (from 25% to 12% after overnight incubation)
and the 10-mer, whereas there was an increase in the 9-mer
product (Figure 3C and Table 1). When an E/S ratio of half was
used, 11-mer product generation was restored by 25% with
ERAP1 versus 23% with the mix of both enzymes (Figure 3D
and Table 1). These data indicate that both aminopeptidases
exhibit concerted non-destructive proteolytic activity only at
lower concentrations.
Generation without destruction of a natural HRSV 11-
mer ligand by concerted ERAP1 and ERAP2
aminopeptidase peptide trimming
The P194-208 precursor was marginally trimmed by ERAP1
(Figure 4A). In contrast, several N-trimmed products (including
the natural 11-mer ligand) were generated by ERAP2 activity
(Figure 4B). This N-extended precursor was processed
efficiently to various short products, especially the natural 11-
mer ligand, in the presence of both enzymes at both E/S ratios
utilized without any epitope destruction, as evidenced by
detecting only 3-5% of the 10-mer peptide (Figure 4C and 4D
and Table 1). Thus, these results indicate concerted peptide
trimming by human ERAP1 and ERAP2 aminopeptidases to
generate a long natural ligand.
ERAP1 and ERAP2 play no role in the natural HRSV 10-
mer ligand production
The N95-109 synthetic peptide was not trimmed by ERAP1, and
only low amounts of the 14-mer product were detected after
ERAP2 activity at the same E/S ratio used in the four previous
15-mer substrates (data not shown). To confirm this point,
enzymatic reactions with larger amounts of ERAP enzymes
were performed. A pattern was observed similar to the one
shown in previous experiments. The N95-109 substrate was
resistant to the ERAP1 enzyme (Figure 5A). Only one
difference was found with ERAP2: the substrate was trimmed
to the 14-mer product without detection of shorter peptides
(Figure 5B). The mix of both enzymes at both E/S ratios
generated an identical pattern (Figure 5C and 5D). Therefore,
some peptides, such as N95-109, are resistant to individual
ERAP1 and ERAP2 aminopeptidases as well as to their
mixture.
Concerted Endoproteolytic Activity of ERAP 1 and 2
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Figure 2.  Stacked area charts of M163-177 and NS231-45 synthetic peptides digested with purified ERAPs.  M163-177 (panels A-D)
and NS231-45 (panels E-H) (sequences are indicated at the top of the figure and the respective HLA ligands identified by MS are
bolded) synthetic peptides were digested at different times with ERAP enzymes as follows: ERAP1 at an E/S ratio of 1:800 (panels
A and E), ERAP2 at an E/S ratio of 1:800 (panels B and F), both ERAP1 and 2 at an E/S ratio of 1:800 (panels C and G), and both
ERAP1 and 2 at an E/S ratio of 1:1600 (panels D and H). The intensity peaks obtained by MALDI-TOF analysis for all peptides at
each time point were added and taken as 100% for each time point and depicted. The different N-end trimming products detected
are named in their respective region. The results depicted are the mean values of three or four independent experiments.
doi: 10.1371/journal.pone.0079596.g002
Concerted Endoproteolytic Activity of ERAP 1 and 2
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Discussion
This study was undertaken to analyze both ERAP1 and
ERAP2 activity and the possible cooperative effects of these
ER aminopeptidases in the antigen processing of several
HRSV ligands. First, we used mass spectrometry to identify
that ERAP1 and/or ERAP2 N-terminal trimming activities
yielded the respective natural ligands in four of the five HLA-
B27-restricted precursors used. Thus, if these data were typical
of the ER-resident trimming, most precursor peptides could be
substrates for these aminopeptidases, with only a low fraction
of peptides resisting this HLA class I customization.
Our results indicate that cooperative peptide trimming of
M163-177 and NS231-45 precursors by ERAP1 and ERAP2
Table 1. Summary of HRSV HLA-B27 ligands or shorter
peptides generated by ERAP enzymes.















½ d  
M
163-177
YLRSISVRNKDLNTL VRNKDLNTL 2 f 5 35 6 9
NS2
31-45
TRDIITHRFIYLINH HRFIYLINH 7 0 26 11 9
N
191-205
KNEMKRYKGLLPKDI KRYKGLLPKDI 25 2 12 23 11
   36 7 5 8 10
   8 6 47 25 9
P
194-208
AMARLRNEESEKMAK LRNEESEKMAK 4 21 44 38 11
   0 3 3 5 10
N
95-109
VDVTTHRQDINGKEM HRQDINGKEM 0 0 0 0 10
a Ligand detected by mass spectrometry analysis in HRSV-infected cells [11].
b E/S molar ratio 1:800
c E/S molar ratio 1:800 with each enzyme.
d E/S molar ratio 1:1,600 with each enzyme.
e Length of detected product.
f Percentage of detected product after overnight incubation.
doi: 10.1371/journal.pone.0079596.t001
predominantly generated 9-mer peptides as well as the 11-mer
ligand from the P194-208 substrate (and to a lesser extent from
the N191-205 peptide at a low E/S ratio) without destroying the
natural HLA class I ligands. In contrast to many HLA class I
alleles that usually bind peptides 8-10 amino acids in length
(SYFPEITHI database: http://www.syfpeithi.de [13]), HLA-B27
could accommodate peptides up to 13 residues in a bulged
conformation (SYFPEITHI database and [14]). Thus, the
previously reported ERAPs’ N-terminal trimming activity to yield
mainly octamer and nonamer products suggested a
predominant destructive role of these enzymes in the HLA-
B27-restricted ligand antigen processing. The data shown in
the present study indicate that these aminopeptidases could be
relevant in generating extended peptides without destroying
naturally present long ligands or epitopes.
Concerted peptide trimming by human ERAP1 and ERAP2
aminopeptidases was previously described with a single
substrate [9]. Subsequently, the molecular basis for the
ERAP1-ERAP2 heterodimer formation has been speculated
[15]. Our in vitro results with several precursors of the naturally
processed HLA-B27-restricted ligands from human cells that
express both aminopeptidases in their ER lumen indicate that
the HIV envelope protein epitope that is presented by murine
MHC is not a single and rare N-terminal trimming xenogeneic
event generated by the cooperative effect of both enzymes in
the antigen processing of MHC class I ligands and reinforce the
hypothesis that ERAP1 and ERAP2 have evolved to perform
joint actions modulating the repertoire of ligands and epitopes
presented by the HLA class I molecules in human cells.
In addition, similar to our present report, a concerted
endoproteolytic activity by caspase 5 and 10 proteases was
required for the digestion of a 19-mer peptide with two amino-
and carboxy-terminal extensions of five residues [16] to
generate a 9mer peptide, which is a natural epitope
endogenously processed from murine cytomegalovirus pp69
phosphoprotein [17]. Thus, the concerted activity of related and
even unrelated [18,19] enzymes may not be a rare event in
antigen processing of specific epitopes and its relevance must
be evaluated in future studies with other epitopes.
Our results indicating in vitro cooperative peptide trimming by
ERAPs enzymes must be expanded in future analyzing the
antiviral CD8+ T cell responses against these HRSV ligands
from human infected-individuals using knocking or silenced
cells in each individual aminopeptidase to describe the in vivo
relevance of the concerted trimming phenomenon by ERAP1
and ERAP2.
Concerted Endoproteolytic Activity of ERAP 1 and 2
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Figure 3.  Stacked area charts of the N191-205 synthetic peptide digested with purified ERAPs.  The N191-205 synthetic peptide
(sequence indicated at the top of the figure and the 11-mer identified by MS is bolded) was digested at different times with ERAP
enzymes as follows: ERAP1 at an E/S ratio of 1:800 (panel A), ERAP2 at an E/S ratio of 1:800 (panel B), both ERAP1 and 2 at an
E/S ratio of 1:800 (panel C), and both ERAP1 and 2 at an E/S ratio of 1:1600 (panel D). The results depicted as Figure 2 are the
mean values of three or four independent experiments.
doi: 10.1371/journal.pone.0079596.g003
Concerted Endoproteolytic Activity of ERAP 1 and 2
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Figure 4.  Stacked area charts of the P194-208 synthetic peptide digested with purified ERAPs.  The P194-208 synthetic peptide
(sequence indicated at the top of the figure and the 11-mer identified by MS is bolded) was digested at different times with ERAP
enzymes as follows: ERAP1 at an E/S ratio of 1:800 (panel A), ERAP2 at an E/S ratio of 1:800 (panel B), both ERAP1 and 2 at an
E/S ratio of 1:800 (panel C), and both ERAP1 and 2 at an E/S ratio of 1:1600 (panel D). The results depicted as Figure 2 are the
mean values of three or four independent experiments.
doi: 10.1371/journal.pone.0079596.g004
Concerted Endoproteolytic Activity of ERAP 1 and 2
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Figure 5.  Stacked area charts of the N95-109 synthetic peptide digested with purified ERAPs.  The N95-109 synthetic peptide
(sequence indicated at the top of the figure and the 9-mer identified by MS is bolded), was digested at different times with ERAP as
follows: ERAP1 at an E/S ratio of 1:200 (panel A), ERAP2 at an E/S ratio of 1:200 (panel B), both ERAP1 and 2 at an E/S ratio of
1:200 (panel C), and both ERAP1 and 2 at an E/S ratio of 1:400 (panel D). The results depicted as Figure 2 are the mean values of
two independent experiments.
doi: 10.1371/journal.pone.0079596.g005
Concerted Endoproteolytic Activity of ERAP 1 and 2
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Supporting Information
Figure S1.  Stacked area charts of mixtures of 15-mer, 12-
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